Management of Menopause-Related Symptoms
Authors: F. William Danby
Journal: Annals of Internal Medicine (2005)

Letters6 December 2005Management of Menopause-Related SymptomsF. William Danby, MDF. William Danby, MDFrom Dartmouth Medical School, Hanover, NH 03755.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-11-200512060-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The National Institutes of Health conference statement (1) notes that therapy with conjugated equine estrogen at doses equivalent to 0.625 mg increases the risk for serious disease events (specifically stroke, deep venous thrombosis, and pulmonary embolism) and, when combined with progestin medroxyprogesterone acetate, for coronary events and breast cancer. In studies in which women were treated for 5 to 7 years, increased risk for coronary and thromboembolic events started to emerge in the first year of use. Risk for stroke started to increase after 2 years of use, and risk for breast cancer started to increase after ...References1. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142:1003-13. [PMID: 15968015] LinkGoogle Scholar2. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, et al. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res. 2001;61:293-302. [PMID: 11196177] MedlineGoogle Scholar3. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol. 2003;85:473-82. [PMID: 12943738] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: F. William Danby, MDAffiliations: From Dartmouth Medical School, Hanover, NH 03755.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNational Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related SymptomsNIH State-of-the-Science Panel*Management of Menopause-Related Symptoms Carol M. Mangione , Donna L. Washington , and Paul Woolf Metrics Cited byIntravaginal Administration of Human Type III Collagen-Derived Biomaterial with High Cell-Adhesion Activity to Treat Vaginal Atrophy in RatsNormal Reproductive and Endocrine Life Stages: The Impact on Sleep DisordersIn Vitro Estrogenic and Breast Cancer Inhibitory Activities of Chemical Constituents Isolated from Rheum undulatum L.Effects of black cohosh and estrogen on core body and tail-skin temperatures in ovariectomized rats by telemetric monitoring with dual thermistor probesMemory Decline in Peri- and Post-menopausal Women: The Potential of Mind–Body Medicine to Improve Cognitive PerformanceAcupuncture for hot flashes 6 December 2005Volume 143, Issue 11Page: 845-846KeywordsBreast cancerDose equivalentEpitheliumEstradiolEstrogensObstetrics and gynecologyProgesteronePulmonary diseasesPulmonary embolismStroke ePublished: 6 December 2005 Issue Published: 6 December 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...